Compare CORT & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | ROIV |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 26.2B |
| IPO Year | 2001 | 2021 |
| Metric | CORT | ROIV |
|---|---|---|
| Price | $111.86 | $35.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $96.50 | $28.94 |
| AVG Volume (30 Days) | 1.3M | ★ 4.8M |
| Earning Date | 04-30-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $761,407,000.00 | $8,260,000.00 |
| Revenue This Year | $26.08 | N/A |
| Revenue Next Year | $26.98 | $744.61 |
| P/E Ratio | $1,267.14 | ★ N/A |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $11.54 |
| 52 Week High | $122.21 | $37.00 |
| Indicator | CORT | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 65.59 | 54.80 |
| Support Level | $76.41 | $33.01 |
| Resistance Level | $122.21 | $36.35 |
| Average True Range (ATR) | 5.21 | 1.26 |
| MACD | 0.55 | 0.04 |
| Stochastic Oscillator | 72.40 | 63.92 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.